24/7 Medical Monitoring

In today’s clinical research environment, speed and safety are non-negotiable. Whether it’s a Phase I oncology trial or a large-scale global program, the ability to detect risks early, respond to medical queries in real-time and ensure participant safety is essential to a trial’s success.

At My Medical Department, we understand that clinical trials don’t sleep and neither should your medical oversight.

What Is Medical Monitoring?

Medical Monitoring is more than just data review. It’s about active, ongoing medical oversight that ensures patient safety, scientific integrity and protocol compliance across every stage of a clinical trial.

Our services include:

• In-depth analysis and interpretation of clinical data
• Participation in Safety Review Committees (SRCs) and Data Safety Monitoring Boards (DSMBs)
• 24/7 availability to address investigator queries and emerging safety signals
• Proactive implementation of risk mitigation strategies that safeguard trial integrity

Why 24/7 Matters

Delays in responding to safety concerns can jeopardise more than your timelines. They can compromise patient well-being.

MMD’s trans-global medical monitoring team spanning the UK, Australia and Latin America, enables seamless round-the-clock coverage. Our physicians are available whenever and wherever they’re needed, ensuring no critical signal is missed due to time zone limitations.

This global setup allows us to offer a truly follow-the-sun model, providing continuous oversight without delay.

Built for Risk Mitigation

Every trial carries risk. Our job is to manage it, decisively and expertly.

By identifying potential safety issues early and working closely with investigators, we help our clients prevent protocol deviations, improve data quality and make informed go/no-go decisions faster.

Our experienced physicians don’t just observe, they collaborate, advise and act.

Real Clients, Real Impact

“The MMD team have been a total pleasure to work with during a large, global fast paced trial that requires plenty of medical input for sites and our CRO team across Australia, New Zealand, and the United States.

MMD have always been very prompt to address any questions from sites and kept our CRO teams proactively informed with all the site activities associated to patient safety, eligibility etc.”

Director of Project Management –
Harvest Integrated Research Organization (HiRO)

We’re proud to support companies of all sizes. From emerging biotechs to multinational pharmaceutical leaders and CROS.

Why Choose MMD?

• ✅ Experienced physicians and scientists
• ✅ Experience across therapy areas and study phases
• ✅ 24/7 global availability
• ✅ Cost-effective, on-demand engagement
• ✅ Proven track record with global pharma partners

We’re not just a vendor. We are your strategic medical partner, dedicated to keeping your trial on track and your patients safe.

---

Ready to Enhance Your Trial’s Oversight?

Let’s talk about how our Medical Monitoring service can support your next clinical program.

📩 Email us at enquiries@mymedicaldepartment.com
🌐 Visit www.mymedicaldepartment.com

Pharmaceutical Medical Expertise. Anytime. Anywhere.

Why Australia stands out for biotech companies.

When it comes to the biotech industry, tax efficiency is a crucial aspect that can significantly impact a company’s bottom line. For biotech firms, the journey from research and development to bringing a product to market is often long and expensive. Therefore, understanding and leveraging tax incentives can make a substantial difference. One country that stands out in this regard is Australia, offering a range of benefits that make it an attractive destination for biotech companies.

Why Australia?

Australia has positioned itself as a global hub for biotech and medtech innovation. The country is home to a dynamic and rapidly growing biotech sector, supported by a robust regulatory framework, generous tax incentives, and a collaborative research environment. These factors combine to create a fertile ground for biotech companies looking to optimise their tax efficiency and drive innovation.

R&D Tax Incentives.

One key advantage of operating in Australia is the Research and Development (R&D) Tax Incentive program. This program encourages companies to engage in R&D activities by offering significant tax offsets. Eligible companies can receive a refundable tax offset of up to 43.5% of their R&D expenditures, a substantial reduction in the financial burden of R&D. This allows companies to reinvest savings into further research and development, providing a reassuring financial cushion.

The R&D Tax Incentive benefits early-stage biotech companies that invest heavily in research and development. By reducing the cost of R&D, these companies can extend their financial runway and accelerate the development of new products. Additionally, the incentive is available to domestic and international companies, making Australia an attractive destination for global biotech firms.

How Australia’s regulatory environment supports the market.

Australia’s regulatory environment is another significant advantage. The Therapeutic Goods Administration (TGA) is known for its efficient and rigorous regulatory processes, which can expedite the approval of new drugs and medical devices. This streamlined approach allows biotech companies to bring their products to market faster, reducing time-to-market and associated costs. For example, the TGA’s fast-track approval process has enabled companies to move from concept to clinical trials in as little as eight months, instilling confidence in the efficiency of the process.

Moreover, Australia’s clinical trials system is both sophisticated and cost-effective. The country offers a high-quality clinical trial infrastructure supported by world-class research institutions and a skilled workforce. This infrastructure makes it an ideal location for conducting clinical trials, a critical component of biotech development. The cost savings associated with conducting trials in Australia can be significant, further enhancing the overall tax efficiency for biotech companies and providing a sense of financial security.

In addition to the R&D Tax Incentive, Australia offers other tax benefits that can enhance the financial efficiency of biotech firms. For instance, the country has a relatively low corporate tax rate compared to other developed nations, which can result in substantial tax savings. Furthermore, Australia has a network of double taxation agreements with numerous countries, which can help mitigate the risk of double taxation on international income.

Australia’s commitment to fostering innovation is evident in its support for the biotech sector. The government has established various funding programs and grants for biotech research and commercialisation. These initiatives provide companies with additional financial support, helping them navigate the costly and complex process of bringing new products to market.

Another key benefit is Australia’s collaborative research environment. The country is home to leading universities and research institutions collaborating actively on innovative projects with biotech companies. This culture of collaboration drives scientific discovery and provides companies with access to cutting-edge research and expertise. Biotech firms can leverage additional resources and knowledge by partnering with these institutions, further enhancing their R&D efforts.

Comparing Australia to Other Countries.

While Australia offers numerous advantages for biotech companies, it’s essential to consider how it stacks up against other countries. The United States, for example, has historically been a major player in the biotech industry, offering substantial R&D tax credits and a large market for biotech products. However, recent changes in U.S. tax policy, such as the Tax Cuts and Jobs Act (TCJA), have altered the landscape. The TCJA reduced the corporate tax rate but also introduced measures that could impact the tax efficiency of biotech firms, such as the requirement to capitalise and amortise R&D expenses over several years.

The European Union.

In contrast, the European Union (EU) offers a variety of tax incentives and grants to support biotech innovation. Countries like Ireland and the Netherlands are known for favourable tax regimes, including low corporate tax rates and generous R&D tax credits. However, the complexity of navigating multiple regulatory environments within the EU can pose challenges for biotech companies.

Asia and Singapore.

Singapore is another notable contender. It offers a highly competitive tax regime with significant incentives for R&D activities. The country provides a range of grants and tax deductions to support innovation, making it an attractive destination for biotech firms looking to optimise their tax efficiency.

While Australia offers a compelling combination of generous tax incentives, a supportive regulatory framework, and a collaborative research environment, it’s important to note that there are also potential risks and challenges. Companies should carefully evaluate their options to determine the best fit for their needs.

For more detailed information on tax planning strategies for biotech firms, you can explore articles like Tax Planning For Life Sciences Amid Shifting Policies and Navigating Tax Planning for Biotech Firms. Additionally, insights on Australia’s biotech advantages can be found in Australia’s biotech and medtech powerhouse and Australia’s Little-Known Biotech Advantages and Risks.

Should you want to learn more about how My Medical Department can support your organisation? Click here.

Expanding into international markets in the healthcare and pharmaceutical industry is a complex endeavour. It’s a landscape fraught with challenges, from regulatory hurdles to cultural differences. One effective strategy to navigate this terrain is to partner with local representatives who are well-versed in the target region’s regulatory environment, cultural nuances, and market dynamics. In this blog, we’ll delve into the benefits of this approach for international sponsors, offering insights on selecting the right partner. This strategic alliance can streamline communication and project management, increasing efficiency and reducing risk.

Benefits of Local Representation

1. Regulatory Compliance: Local representatives deeply understand their region’s regulatory landscape and specific requirements, making it easier to navigate complex processes and ensure that projects meet all the necessary criteria. This expertise helps prevent potential delays and costly mistakes associated with non-compliance.
2. Cultural Sensitivity: A local representative can provide valuable insights into the cultural norms and expectations of the target market, enabling international sponsors to tailor their approach accordingly. This cultural understanding can improve stakeholder relationships, more effective communication, and ultimately, tremendous project success, fostering a sense of connection. Effective Communication: Local representatives are often fluent in the local language and clearly understand regional dialects and terminology. This advantage facilitates communication with local stakeholders, regulatory authorities, and suppliers, helping to avoid misunderstandings and promote seamless collaboration.

Cost and Time Savings.

By partnering with a local representative, international sponsors can reduce the time and resources spent on market research, logistics management, and navigating regulatory processes. The local representative’s existing networks and regional expertise allow sponsors to focus on their core competencies and achieve their goals more efficiently, promoting a sense of productivity. Risk Mitigation: A knowledgeable local representative can identify potential risks, challenges, and opportunities for their region. By leveraging this expertise, international sponsors can minimise the risk of setbacks or adverse outcomes associated with launching or managing healthcare products and services in the target market, providing a sense of security and relief. Tips for Choosing the Right Local Representative

1. Relevant Experience: Look for a local representative with a proven healthcare and pharmaceutical industry track record who has successfully handled similar projects for other sponsors. This experience is essential to guaranteeing the representative’s competence in managing complex projects and ensuring compliance.
2. Strong Network: Choose a local representative with an established network of contacts and relationships with key regional stakeholders. This strong network can provide invaluable support in facilitating project delivery, overcoming barriers, and expediting communication with decision-makers.
3. Clear Communication: Effective communication is critical to a successful partnership between an international sponsor and a local representative. Ensure that your chosen partner demonstrates excellent communication skills, is responsive to inquiries, and is transparent about their progress and any challenges faced during the project.
4. Flexibility and Adaptability: Partner with a local representative capable of adapting to changing project requirements and maintaining a flexible work style. This adaptability is essential to address unforeseen challenges and pivot strategies as needed to achieve project success.

When choosing a local representative, it’s crucial to consider their cultural fit with your organisation. A great local representative should share your company’s values and have a compatible working style. Assess your potential partners for their understanding of your company’s needs and expectations. This ensures that your collaboration is not just productive but also efficient.

Partnering with a local representative can significantly enhance an international sponsor’s likelihood of success as they venture into new healthcare and pharmaceutical markets. The right local representative can provide invaluable insights, expertise, and guidance, ultimately helping to mitigate risks, streamline communication, and improve the overall efficiency of your projects. To maximise this critical partnership, consider experience, network, communication skills, flexibility, and cultural fit before choosing your ideal local representative.

Thank you for reading! If you’re looking for expert support in the medical field, visit My Medical Department. Our physician-led consultancy offers tailored solutions to meet your needs, ensuring excellence throughout your product’s lifecycle. Let us partner with you to navigate the complexities of healthcare with confidence and expertise.

Streamlining ISS Strategy for Enhanced Data Generation in a Specialty Pharmaceutical Firm

The Challenge

As a speciality pharmaceutical company with a relatively new Medical Science Liaison (MSL) force, our client recognised the need to optimise their data generation capabilities. They sought the expertise of MMD to work on their Investigator-Sponsored Studies (ISS) strategy. This support aimed to ensure a steady scientific and promotional communications data stream. This collaborative effort addressed our concerns about our client’s ISS’s frequency, cost, and duration.

Developing a Comprehensive Strategy

MMD’s approach was comprehensive. We began by extensively collaborating with the company’s scientific (MSLs, Medical Affairs) and commercial (Marketing, Sales, Market Access) teams. We meticulously mapped out the scientific and promotional data requirements for both the short and long term. In addition, we conducted a detailed analysis of their major competitor data and key messages. This rigorous process led to a data generation strategy that fully aligned with their needs and instilled confidence in the strategy.

“Thank you so much; you have solved our data generation issues. I am sure, we will now have a regular stream of externally usable data.”​ Senior Medical Affairs Leader

Streamlining the ISS Process

Moreover, we worked on optimising the ISS process and reviewing and refining approval processes. We wrote Standard Operating Procedures (SOPs), developed templates, and provided training to all involved to ensure consistency. Next, we developed external materials and collaborated with their agency to create a website for ISS.​

Results

As a result, the speciality pharmaceutical company was able to benefit from the following:

• Our comprehensive data generation strategy, tailored for both short—and long-term needs, filled the gaps and provided a clear roadmap for future data collection. This strategy fully aligned with the company’s data generation needs, ensuring a steady stream of scientific and promotional communications data.
• To support the new strategy, we introduced a robust system, streamlined processes, and user-friendly templates. These tools were designed to simplify and standardise the ISS process, making it more efficient and cost-effective.
• Our efforts in aligning and training the teams have equipped them with the necessary skills and knowledge to implement the new strategy effectively. They are now well-prepared to drive the ISS process forward, ensuring a steady data stream for the company’s scientific and promotional communications. By working closely with the company and embracing a systematic approach, MMD optimised the investigator-sponsored studies process, enabling the speciality pharmaceutical company to enhance its data generation capabilities.

MMD provides tailored support to businesses by optimising data generation capabilities and enhancing investigator-sponsored studies (ISS) strategies. By collaborating closely with clients, MMD aligns scientific and promotional data requirements with short—and long-term goals, ensuring a competitive edge in the market. MMD offers comprehensive solutions to meet each business’s unique needs through process optimisation, system implementation, and team alignment.

To explore MMD’s services and discuss how they can support your organisation’s success, visit their website or contact their team via email or phone. Begin the conversation and unlock your business’s potential.